Abiomed Slips to Neutral - Analyst Blog

By
A A A

On Jun 17, we downgraded cardiac assist devices maker, Abiomed ( ABMD ), to Neutral, as we believe that the positives from its last earnings have already been factored into the current stock price.

Why the Downgrade?

Estimates for Abiomed have been declining since it reported fourth quarter fiscal 2013 results on May 2. Following the results, the Zacks Consensus Estimate for fiscal 2014 slipped 25% to 33 cents per share. The Zacks Consensus Estimate for fiscal 2015 has also declined significantly (down 27% to 54 cents per share). With the Zacks Consensus Estimate for both fiscal 2014 and 2015 going down, the company now has a Zacks Rank #3 (Hold).

The global healthcare environment is still challenging. Thus, Abiomed's significant exposure in Europe remains a cause of concern. Moreover, the company is facing regulatory issues in the U.S. regarding its Impella products. Research and development initiatives to meet regulatory requirements might add pressure on the company's margins. Competition from other industry leaders such as Thoratec ( THOR ) and fluctuating foreign currency remain additional headwinds.

On the positive side, Abiomed enjoys a strong demand for its Impella products. Multiple near-term drivers, including new products and clinical trials, should further boost the use of Impella. However, the company's sole dependence on a single product line is risky, as any kind of disruption or delay in Impella sales will adversely affect the business

Abiomed's fourth-quarter fiscal 2013 revenues of $43.7 million as well as EPS of 9 cents beat the Zacks Consensus Estimate of $42 million and 7 cents, respectively. The company posted record revenues and patient support in fiscal 2013. However, we do not see any near-term catalysts that could boost the share price going forward.

Other Med-Tech Stocks to Consider

While we remain on the sidelines regarding Abiomed, other stocks such as Natus Medical ( BABY ) and Myriad Genetics ( MYGN ) warrant a look. These stocks carry a Zacks Rank #1 (Strong Buy).



ABIOMED INC (ABMD): Free Stock Analysis Report

NATUS MEDICAL (BABY): Free Stock Analysis Report

MYRIAD GENETICS (MYGN): Free Stock Analysis Report

THORATEC CORP (THOR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ABMD , BABY , MYGN , THOR

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

112,007,213
  • $14.79 ▼ 2.12%
79,492,830
  • $17.05 ▲ 0.24%
63,236,947
  • $56.63 ▲ 7.54%
55,553,482
  • $3.41 ▼ 3.94%
53,662,885
  • $14.19 ▼ 3.47%
52,606,858
  • $100.75 ▲ 0.64%
39,074,810
  • $4.84 ▼ 2.22%
38,681,912
  • $25.62 ▲ 0.79%
As of 9/30/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com